Peak Bone Mass After Exposure to Antenatal Betamethasone and Prematurity: Follow-up of a Randomized Controlled Trial
Open Access
- 1 August 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 21 (8), 1175-1186
- https://doi.org/10.1359/jbmr.060516
Abstract
Small birth size is associated with reduced adult bone mass. We determined if antenatal betamethasone exposure, birth weight, or prematurity affects peak bone mass in 174 adults. Antenatal betamethasone exposure did not. Lower birth weight and prematurity predicted reduced adult height. Slower fetal growth rather than prematurity predicted lower bone mass, but this lower bone mass was appropriate for reduced adult height. Introduction: Small size at birth is reported to be associated with lower bone mass in adulthood. However, previous studies have not distinguished the relative contributions of length of gestation and fetal growth to size at birth. Fetal exposure to excess glucocorticoids has been proposed as a core mechanism underlying the associations between birth size and later disease risk. Antenatal glucocorticoids are given to pregnant women at risk for preterm delivery for the prevention of neonatal respiratory distress syndrome in their infants. We determined the relationship of antenatal exposure to betamethasone, birth weight, and prematurity to peak bone mass and femoral geometry in the adult survivors of the first randomized trial of antenatal glucocorticoids. Materials and Methods: We studied 174 young adults (mean age, 31 years) whose mothers participated in a randomized trial of antenatal betamethasone. Mothers received two doses of intramuscular betamethasone or placebo 24 h apart. Two thirds of participants were born preterm (p = 0.002). A lighter birth weight (p ≤ 0.001) and lower gestational age (p = 0.013) were associated with shorter stature (height Z scores) at age 31 years. Prematurity had no effect on peak bone mass or femoral geometry. However, lower birth weight, independent of gestational age, was associated with lower later bone mass (p < 0.001 for lumbar spine and total body, p = 0.003 for femoral neck BMC). These effects on bone mass were related to bone size and not to estimates of volumetric density. In the femur, lower birth weight, independent of gestational age, was associated with narrowing of the upper shaft and narrow neck regions. Conclusions: Antenatal betamethasone exposure does not affect peak bone mass or femoral geometry in adulthood. Birth weight and prematurity predict adult height, but it is slower fetal growth, rather than prematurity, that predicts lower peak bone mass. The lower peak bone mass in those born small is appropriate for their adult height.Keywords
This publication has 42 references indexed in Scilit:
- Early life influences on serum 1,25 (OH)2 vitamin DPaediatric and Perinatal Epidemiology, 2005
- Statistics, not memories: what was the standard of care for administering antenatal steroids to women in preterm labor between 1985 and 2000?Obstetrics & Gynecology, 2003
- Association of birth weight with osteoporosis and osteoarthritis in adult twinsRheumatology, 2003
- Body composition in infants with chronic lung disease after treatment with dexamethasoneActa Paediatrica, 2002
- Effects of prematurity, intrauterine growth status, and early dexamethasone treatment on postnatal bone mineralisationArchives of Disease in Childhood: Fetal & Neonatal, 2000
- The relationship between anthropometric measurements and fractures in womenBone, 1996
- Body Height and Hip Fracture: A Cohort Study of 90 000 WomenInternational Journal of Epidemiology, 1995
- Are preterm infants at risk for subsequent fractures?Archives of Disease in Childhood, 1989
- Bone mineral content in bronchopulmonary dysplasia.Archives of Disease in Childhood, 1987
- Non-invasive measurement of long bone cross-sectional moment of inertia by photon absorptiometryJournal of Biomechanics, 1984